Home Administration of Zoledronic Acid for Breast Cancer
Author Information
Author(s): Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D
Primary Institution: Christie Hospital NHS Trust
Hypothesis
Does home administration of zoledronic acid improve pain and quality of life in breast cancer patients with bone metastases compared to hospital administration?
Conclusion
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases, especially when administered in the community setting.
Supporting Evidence
- Patients reported significant reductions in worst pain and average pain after treatment in the community setting.
- Overall global health status showed a significant median improvement of 8.3%.
- Physical, emotional, and social functioning showed significant overall improvement.
Takeaway
This study shows that giving a medicine called zoledronic acid at home helps breast cancer patients feel less pain and live better lives.
Methodology
A phase IIIb, multicentre, randomised, open-label, crossover study comparing zoledronic acid administration in community vs hospital settings.
Limitations
The study may not be generalizable to patients receiving chemotherapy or those with abnormal renal function.
Participant Demographics
Adult patients with histologically confirmed breast cancer and at least one bone metastasis, receiving hormonal therapy.
Statistical Information
P-Value
P=0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website